Company intelligence / Profile preview

Myovant Sciences

Brisbane, California, United Statesmyovant.gcs-web.com ↗

Ownership: Private
Employees: ~750
Development stage: Commercial

Overview

Myovant has developed relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist for conditions such as heavy menstrual bleeding associated with uterine fibroids[2]. They also have MVT-602, an oligopeptide kisspeptin agonist for female infertility treatment[2].

Therapeutic areas: Women's HealthOncologyEndocrinology
Modalities: Small moleculesoligopeptide
Industry: Biotech

Drug pipeline

2 assets

relugolix

Commercial

Indications: Prostate cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Myovant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myovant Sciences.

Explore the full profile